responsive to chemotherapy; however, essentially all patients who respond to drug treatment will relapse and die of drugBone marrow specimens are collected into syringes containresistant disease. This disease is therefore considered a paraing preservative-free heparin and maintained at room temdigm for studying the development of acquired drug resistance perature prior to processing. If specimens are being shipped in the clinic. Natural product agents are frequently used in the treatment of myeloma, especially vincristine and doxorubicin.
Introduction

Detection of Pgp by immunocytochemistry (ICC) Multiple myeloma represents a hematologic malignancy
We have previously reported on the optimization of ICC for which is generally considered drug sensitive; however, detection of Pgp in myeloma cells. We found that for the patients ultimately acquire drug resistance and the disease is monoclonal antibodies C219 and JSB1, optimal fixation considered incurable with treatments available today. It is occurred with cold acetone. 7 Optimal concentrations of the important to determine the mechanisms of drug resistance that two monoclonal antibodies were 1/200 for JSB-1 and 1/100 occur in myeloma so that means of preventing or circumfor C219. As controls, we used the drug-sensitive and -resistventing resistance may be developed. It is highly likely that a ant human myeloma cell lines, 8226/S and 8226/Dox 6 . We number of mechanisms contribute to the overall drug-resistant have recently developed 8226 cell lines with lower levels of phenotype. The most well-described mechanism of drug resistance (three-to four-fold) and are currently optimizing resistance is due to the overexpression of the MDR1 gene and conditions for detection of Pgp using these lower level resistits cognitive protein, P-glycoprotein (Pgp). 1 We, and others, ant cell lines. ICC coupled to computer-assisted single cell have found that the expression of Pgp occurs in drug-resistant densitometry, showed a strong correlation (r = 0.98) between myeloma patients who have been treated with natural product cellular density of Pgp and in vitro resistance to doxorubicin. drugs, including vincristine and doxorubicin. 2, 3 Recently howThe strengths of ICC assays in myeloma include sensitivity of ever, other novel drug resistance genes have been described detection of Pgp and the ability to discriminate between myewhich may participate in clinical drug resistance occurring loma cells and other cells of the bone marrow known to in myeloma patients. These include the multidrug resistance express Pgp. A weakness of the assay is the potential for falseprotein (MRP) and the lung resistance protein (LRP). 4, 5 Accurpositive results due to antigen crossreactivity. The latter may ate methods for detecting drug-resistant gene expression in be avoided by using a panel of antibodies which recognize clinical specimens are needed to determine the clinical different epitopes of Pgp. relevance of each individual mechanism.
Multiple techniques have been developed to detect the expression of drug resistance genes (MDR1/Pgp, MRP and FCM analysis of myeloma specimens LRP) in patient specimens with multiple myeloma. These methods include the detection of gene expression (RT/PCR), Pgp: plasma cell double labeling gene product (immunocytochemistry, flow cytometry) and protein function (flow cytometric assay for drug efflux). [6] [7] [8] [9] For Cells (1 × 10 6 ) reacted with 250 l of normal rabbit serum at the purpose of this discussion, we will focus on the detection 4°C for 15 min, then with 5 g of MRK16 (Kamiya, Thousand of the MDR1/Pgp in myeloma specimens.
Oaks, CA, USA) or 4E3 (Signet, Dedham, MA, USA) for 30 min at 4°C. 10 An IgG2a is used as an isotype control antibody. Cells are washed, then reacted with 5 g of fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse F(ab) 2 nucleotide downstream primer is complimentary to nucleoaccumulation and ability to reverse resistance with a chemotides 1033-1009 of the MDR1 cDNA sequence, resulting in sensitizer. This variation in Pgp expression in patient specia 402 base pair amplicon. mens emphasizes the probability that multiple mechanisms of resistance exist in a single patient. Efforts to reverse clinical MDR1 upstream primer resistance must take into account individual patient hetero-5′-CTG GTG TTT GGA GAA ATG ACA G-3′ geneity for Pgp expression. It is possible that eliminating the MDR1 downstream primer Pgp-positive cells by using chemosensitizers will result in the 5′-CCC AGT GAA AAA TGT TGC CAT TGA C-3′ emergence of myeloma cells that are resistant by non-Pgp
The 402 base pair MDR1 amplicon was amplified using the mechanisms. Our preliminary clinical studies using chemofollowing conditions: cDNA denaturation for 5 min at 95°C; sensitizers to reverse MDR confirm this suspicion.
35 cycles of PCR: cDNA denaturation for 45 s at 95°C, primer annealing for 30 s at 60°C, primer extension for 45 s at 72°C; RT/PCR analysis for quantitating MDR1 expression and primer extension for 5 min at 72°C.
In 1993, we reported on the development of a quantitative RT/PCR analysis for MDR1 in myeloma specimens that used Histone 3.3 cDNA amplification a unique 'mimic' internal standard for quantitation. 6 The 'mimic' internal standard was created by designing a synthetic mdr1 RNA that used the same primers for cellular analysis Five microliters of cDNA were used for the analysis of H3.3 of MDR1 message. We found that this assay provided a very gene expression and was amplified in a total volume of 50 l accurate and reproducible means of quantitating MDR1 RNA; with the addition of the following reagents: 1 × PCR buffer; however, it is very labor intensive. Recently, we have found 25 pmol of each H3.3 specific primer; 1.25 Ci [␣-32 P]dCTP; that using histone H3. The 214 base pair H3.3 amplicon was amplified using the RNA isolation following conditions: cDNA denaturation for 5 min at 95°C; 23 cycles of PCR: cDNA denaturation for 45 s at 95°C, primer Total RNA was isolated from cells using guanidine isothiocyanate lysis solution followed by centrifugation through a annealing for 30 s at 60°C, primer extension for 45 s at 72°C; and primer extension for 5 min at 72°C. cesium chloride gradient.
Figure 1
Serial dilution of MDR1 PCR product on a polyacrylamide gel from 8226/DOX6 cells. Using the standard calibration curves, values can be assigned to individual patients for MDR1 mRNA signal (⌬). This allows for interpatient comparisons, as well as intrapatient comparisons at different points in time.
Product analysis
Conclusions
The challenge to measure drug resistance genes in clinical PCR products were quantitated by fractionation of 10 l of specimens is formidable, but not insurmountable. 11 The develthe total product volume through a 5% non-denaturing 1×-opment of multiple assays to measure gene expression, pro-TBE polyacrylamide gel, dried on a gel dryer, and exposed to tein product, and ultimately protein function, will allow us to a phosphorimaging plate and quantitated with the phosphordetermine the significance and overall contribution of drug imaging system (Molecular Dynamics, Sunnyvale, CA, USA) resistance genes in various cancers. In this report, we have using Image Quant 3.3 software.
described our approach to measuring MDR1/Pgp in myeloma specimens. We are adapting these techniques to other drugresistant genes (MRP, LRP) which may play a role in the development of overall clinical drug resistance.
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